bone loss semaglutide Type 2 diabetes: may help protect health Comparative safety and side effects

No waiting around for ever

Nihon Rinsho 2007;65(6):1005-1010

The STEER study investigated the risk of major adverse cardiovascular events (MACE) with Wegovy (semaglutide) 2.4 mg compared with tirzepatide treatment in people with overweight or obesity and established CVD without diabetes

Rare but serious risks include pancreatitis and gallbladder issues

Between September 13 and November 22, 2021, a total of 709 individuals were screened, and 667 were included in the study

BPC 157 can be particularly beneficial for athletes recovering from sports injuries or individuals dealing with chronic conditions like tendonitis or muscle strains and/or are looking to improve muscle strength